Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?

被引：0
|
作者：
Verma, S.
Mittmann, N.
Bernard, L.
Thompson, M.
Chan, B.
Asmar, L.
Jones, S.
机构：
[1] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[3] Cornerstone Res Grp Inc, Burlington, ON, Canada
[4] US Oncol Res, Houston, TX USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378S / 378S
页数：1
相关论文
共 42 条
  • [31] ADJUVANT CHEMOHORMONAL THERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, AND PREDNISONE (CMFP) OR CMFP PLUS TAMOXIFEN COMPARED WITH CMF FOR PREMENOPAUSAL BREAST-CANCER PATIENTS - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL
    TORMEY, DC
    GRAY, R
    GILCHRIST, K
    GRAGE, T
    CARBONE, PP
    WOLTER, J
    WOLL, JE
    CUMMINGS, FJ
    CANCER, 1990, 65 (02) : 200 - 206
  • [32] NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer
    Fehrenbacher, Louis
    Jeong, Jong-Hyeon
    Rastogi, Priya
    Geyer, Charles E.
    Paik, Soonmyung
    Ganz, Patricia A.
    Land, Stephanie R.
    Costantino, Joseph P.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia
    Augusto Guevara-Cuellar, Cesar
    Parody-Rua, Elizabeth
    Paula Rengifo-Mosquera, Maria
    Del Mar Conde-Crespo, Maria
    Maicol Nunez-Castro, Jhon
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 109 - 118
  • [34] NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.
    Swain, S. M.
    Jeong, J-H
    Geyer, C. E.
    Costantino, J. P.
    Pajon, E. R.
    Fehrenbacher, L.
    Atkins, J. N.
    Polikoff, J.
    Vogel, V. G.
    Erban, J. K.
    Livingston, R. B.
    Perez, E. A.
    Mamounas, E. P.
    Ganz, P. A.
    Land, S. R.
    Wolmark, N.
    CANCER RESEARCH, 2009, 69 (02) : 81S - 81S
  • [35] NSABP B-47: A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
    Fehrenbacher, L.
    Jeong, J-H
    Rastogi, P.
    Geyer, C. E.
    Paik, S.
    Ganz, P. A.
    Land, S. R.
    Costantino, J. P.
    Swain, S. M.
    Mamounas, E. P.
    Wolmark, N.
    CANCER RESEARCH, 2011, 71
  • [36] Phase III, randomized study of docetaxel (T) plus capecitabine (X) (TX) followed by cyclophosphamide (C) plus epirubicin (E) plus X (CEX) vs. T followed by C plus E plus fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): An interim safety analysis.
    Joensuu, H
    Hemminki, A
    Tanner, M
    Paija, O
    Kokko, R
    Asola, R
    Johansson, K
    Bono, P
    Elomaa, I
    Kellokumpu-Lehtinen, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 57S - 57S
  • [37] Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pNO) and limited node positive (pN+≤53) breast cancer (BC) patients (pts):: First analysis of toxicity.
    Brain, EGC
    Bachelot, T
    Serin, D
    Graïc, Y
    Eymard, JC
    Extra, JM
    Combe, M
    Nogues, C
    Rouëssé, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 31S - 31S
  • [38] Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial
    Bermejo, Begona
    Ruiz, Amparo
    Ruiz Borrego, Manuel
    Ribelles, Nuria
    Rodriguez-Lescure, Alvaro
    Munoz-Mateu, Montserrat
    Gonzalez, Sonia
    Margeli, Mireia
    Barnadas, Agust
    Ramos Vazquez, Manuel
    del Barco, Sonia
    Calvo, Lourdes
    Mendiola, Cesar
    Crespo, Carmen
    Augusto Rodriguez, Cesar
    Martinez, Eduardo
    Isabel Casas, Maria
    Carmen Camara, M.
    Maria Carrasco, Eva
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN plus and high-risk LN-breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features
    Sparano, Joseph A.
    O'Neill, Anne
    Gray, Robert James
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Badve, Sunil S.
    Baehner, Frederick L.
    Childs, Barrett H.
    Yoshizawa, Carl N.
    Rowley, Steve
    Davidson, Nancy E.
    Shak, Steven
    Goldstein, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin plus cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.
    Joensuu, H.
    Kellokumpu-Lehtinen, P.
    Huovinen, R.
    Jukkola-Vuorinen, A.
    Asola, R.
    Kokko, R.
    Ahlgren, J.
    Bono, P.
    Tanner, M.
    Lindman, M.
    CANCER RESEARCH, 2009, 69 (02) : 84S - 84S
12345